Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging

Nature Communications

Volumn 8, Issue , 2017, Pages

  Cuccarese, Michael F ^a   Dubach, J Matthew ^a   Pfirschke, Christina ^a   Engblom, Camilla ^a   Garris, Christopher ^a   Miller, Miles A ^a   Pittet, Mikael J ^a   Weissleder, Ralph ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; DOCETAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; 5-((5-CHLORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)METHYL)-N-((6-(TRIFLUOROMETHYL)PYRIDIN-3-YL)METHYL)PYRIDIN-2-AMINE; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; NANOPARTICLE; PYRROLE DERIVATIVE;

CANCER; CARCINOGEN; DRUG; HETEROGENEITY; IMMUNE SYSTEM; NANOPARTICLE; THREE-DIMENSIONAL MODELING; TUMOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL INFILTRATION; CONTROLLED STUDY; INTESTINE; LUNG CARCINOMA; LUNG PARENCHYMA; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PANCREAS; QUANTITATIVE ANALYSIS; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; CONFOCAL MICROSCOPY; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG SCREENING; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOLOGY; LEWIS CARCINOMA; LUNG; LUNG TUMOR; MACROPHAGE; METABOLISM; PATHOLOGY; PERFUSION; PROCEDURES; RAW 264.7 CELL LINE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; X-RAY COMPUTED TOMOGRAPHY;

ANIMALIA; MURINAE;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LUNG; LUNG NEOPLASMS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PERFUSION; PYRROLES; RAW 264.7 CELLS; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85012014136     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14293     Document Type: Article

References (62)

1. DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67 (2011).
2. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
3. Wynn, T. A., Chawla, A. & Pollard, J. W. Macrophage biology in development, homeostasis and disease. Nature 496, 445-455 (2013).
4. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
5. Pittet, M. J., Nahrendorf, M. & Swirski, F. K. The journey from stem cell to macrophage. Ann. N. Y. Acad. Sci. 1319, 1-18 (2014).
6. De Palma, M. & Lewis, C. E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23, 277-286 (2013).
7. Mantovani, A. & Allavena, P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 212, 435-445 (2015).
8. Ruffell, B. & Coussens, L. M. Macrophages and therapeutic resistance in cancer. Cancer Cell 27, 462-472 (2015).
9. Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447-462 (2016).
10. Tap, W. D. et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 373, 428-437 (2015).
11. Vadrevu, S. K. et al. Studying the role of alveolar macrophages in breast cancer metastasis. J. Vis. Exp. 26, e54306 (2016).
12. Movahedi, K. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728-5739 (2010).
13. Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938-945 (2015).
14. Yano, S. et al. Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. Cell Cycle 13, 2110-2119 (2014).
15. Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559-563 (2014).
16. Badea, C. T. et al. Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. PLoS ONE 7, e34496 (2012).
17. Yang, M. et al. Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells. Proc. Natl Acad. Sci. USA 100, 14259-14262 (2003).
18. Hoffman, R. M. & Yang, M. Color-coded fluorescence imaging of tumor-host interactions. Nat. Protoc. 1, 928-935 (2006).
19. Yaqoob, Z., Psaltis, D., Feld, M. S. & Yang, C. Optical phase conjugation for turbidity suppression in biological samples. Nat. Photonics 2, 110-115 (2008).
20. Vinegoni, C., Aguirre, A. D., Lee, S. & Weissleder, R. Imaging the beating heart in the mouse using intravital microscopy techniques. Nat. Protoc. 10, 1802-1819 (2015).
21. Chung, K. & Deisseroth, K. Clarity for mapping the nervous system. Nat. Methods 10, 508-513 (2013).
22. Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896-910 (2014).
23. Murray, E. et al. Simple, scalable proteomic imaging for high-dimensional profiling of intact systems. Cell 163, 1500-1514 (2015).
24. Ku, T. et al. Multiplexed and scalable super-resolution imaging of threedimensional protein localization in size-adjustable tissues. Nat. Biotechnol. 34, 973-981 (2016).
25. Richardson, D. S. & Lichtman, J. W. Clarifying tissue clearing. Cell 162, 246-257 (2015).
26. Susaki, E. A. et al. Advanced CUBIC protocols for whole-brain and whole-body clearing and imaging. Nat. Protoc. 10, 1709-1727 (2015).
27. Herculano-Houzel, S. & Lent, R. Isotropic fractionator: a simple, rapid method for the quantification of total cell and neuron numbers in the brain. J. Neurosci. 25, 2518-2521 (2005).
28. Del Monte, U. Does the cell number 10(9) still really fit one gram of tumor tissue. Cell Cycle 8, 505-506 (2009).
29. DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064-1072 (2009).
30. Pfirschke, C. et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343-354 (2016).
31. Miller, M. A. et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat. Commun. 6, 8692 (2015)
32. Scott, G. D., Blum, E. D., Fryer, A. D. & Jacoby, D. B. Tissue optical clearing, three-dimensional imaging, and computer morphometry in whole mouse lungs and human airways. Am. J. Respir. Cell Mol. Biol. 51, 43-55 (2014).
33. Erdag, G. et al. Immunotype and immunohistologic characteristics of tumorinfiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 72, 1070-1080 (2012).
34. Weissleder, R., Nahrendorf, M. & Pittet, M. J. Imaging macrophages with nanoparticles. Nat. Mater. 13, 125-138 (2014).
35. Miller, M. A. et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci. Transl. Med. 7, 314ra183-314ra183 (2015).
36. Daldrup-Link, H. E. et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin. Cancer Res. 17, 5695-5704 (2011).
37. Mayo, J. G. Biologic characterization of the subcutaneously implanted Lewis lung tumor. Cancer Chemother. Rep. 2, 325-330 (1972).
38. Reuben, A. et al. Molecular and immune heterogeneity in synchronous melanoma metastases. J. Immunother. Cancer 3, P262 (2015).
39. Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272 (2013).
40. Zhang, C. et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc. Natl Acad. Sci. USA 110, 5689-5694 (2013).
41. Mok, S. et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 74, 153-161 (2014).
42. Quail, D. F. et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018 (2016).
43. Laoui, D., Van Overmeire, E., De Baetselier, P., Van Ginderachter, J. A. & Raes, G. Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front. Immunol. 5, 489 (2014).
44. Stafford, J. H. et al. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro Oncol. 18, 797-806 (2016).
45. Kamaly, N., Yameen, B., Wu, J. & Farokhzad, O. C. Degradable controlledrelease polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem. Rev. 116, 2602-2663 (2016).
46. Lukinavičius, G. et al. Fluorogenic probes for live-cell imaging of the cytoskeleton. Nat. Methods 11, 731-733 (2014).
47. Tassa, C., Shaw, S. Y. & Weissleder, R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc. Chem. Res. 44, 842-852 (2011).
48. Barton Pai, A. & Garba, A. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud. J. Blood Med. 2012, 77-85 (2012).
49. Provenzano, R. et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4, 386-393 (2009).
50. Harney, A. S. et al. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by tie2hi macrophag derived VEGFA. Cancer Discov. 5, 932-943 (2015).
51. Marx, V. Optimizing probes to image cleared tissue. Nat. Methods 13, 205-209 (2016).
52. Kimura, H. et al. Real-time imaging of single cancer-cell dynamics of lung metastasis. J. Cell Biochem. 109, 58-64 (2010).
53. Kim, E., Yang, K. S., Giedt, R. J. & Weissleder, R. Red Si-rhodamine drug conjugates enable imaging in GFP cells. Chem. Commun. (Camb.) 50, 4504-4507 (2014).
54. Kim, E. et al. Optimized near-IR fluorescent agents for in vivo imaging of Btk expression. Bioconjug. Chem. 26, 1513-1518 (2015).
55. Laughney, A. M. et al. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Sci. Transl. Med. 6, 261ra152 (2014).
56. Rashidian, M. et al. Noninvasive imaging of immune responses. Proc. Natl Acad. Sci. USA 112, 6146-6151 (2015).
57. Thurber, G. M. & Weissleder, R. A systems approach for tumor pharmacokinetics. PLoS ONE 6, e24696 (2011).
58. Looney, M. R. et al. Stabilized imaging of immune surveillance in the mouse lung. Nat. Methods 8, 91-96 (2010).
59. Cortez-Retamozo, V. et al. Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation. J. Clin. Invest. 118, 4058-4066 (2008).
60. Hama, H. et al. Scales: an optical clearing palette for biological imaging. Nat. Neurosci. 18, 1518-1529 (2015).
61. Sylwestrak, E. L., Rajasethupathy, P., Wright, M. A., Jaffe, A. & Deisseroth, K. Multiplexed intact-tissue transcriptional analysis at cellular resolution. Cell 164, 792-804 (2016).
62. Amendola, M., Venneri, M. A., Biffi, A., Vigna, E. & Naldini, L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Biotechnol. 23, 108-116 (2005).